中国药业2025，Vol.34Issue(10)：123-127,5.DOI:10.3969/j.issn.1006-4931.2025.10.027
美金刚辅助治疗抑郁症有效性和安全性Meta分析
Meta-Analysis of the Efficacy and Safety of Memantine Adjuvant Treatment of Depression
摘要
Abstract
Objective To systematically evaluate the efficacy and safety of memantine adjuvant treatment of depression.Methods The randomized controlled trials(RCT)in both Chinese and English for memantine adjuvant treatment of depression in PubMed,Web of Science,The Cochrane Library,Wanfang and VIP databases were searched from the establishment of each database to March 2023.The Jadad scale was used to evaluate the quality of the included literature,and RevMan 5.3 software was used to conduct a Meta-analysis of the efficacy and safety of memantine adjuvant treatment of depression.Results A total of 6 articles were included,among which there were 5 English articles(3 articles from the United States and 2 articles from Iran)and 1 article from China.The Jadad scale score was 5 points for 3 articles,6 points for 2 articles,and 7 points for 1 article.The control group was all treated with placebo.The clinical remission rate between the experimental group and the control group was comparable[OR=1.49,95%CI(0.81,2.73),P=0.20].However,the improvement of Hamilton Depression Rating Scale(HAMD/HDRS)score[MD=-1.46,95%CI(-2.24,-0.69),P=0.000 2]and Montgomery Depression Rating Scale(MADRS)score[MD=-3.06,95%CI(-5.29,-0.83),P=0.007]in the experimental group were better than those in the control group.The incidence of adverse reactions between the experimental group and the control group was comparable(P>0.05).Conclusion Memantine adjuvant treatment for depression is effective in improving the HAMD/HDRS scale scores,and the clinical remission rate and safety are comparable to those of placebo.关键词
抑郁症/美金刚/辅助治疗/随机对照试验/Meta分析Key words
depression/memantine/adjuvant treatment/randomized controlled trials/Meta-analysis分类
药学引用本文复制引用
陈红,陈娇,孟祥军,孔伶俐..美金刚辅助治疗抑郁症有效性和安全性Meta分析[J].中国药业,2025,34(10):123-127,5.基金项目
山东省青岛市科技惠民示范项目[22-3-7-smjk-9-nsh]. （）
